Endocrine resistance – a major cause of breast cancer deaths – can be underpinned by an epigenetic change called DNA methylation, researchers at the Garvan Institute of Medical Research have ...

In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Preclinical studies by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, showed how a new combination therapy for hormone-resistant, ...

Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office ...

For patients with estrogen receptor (ER)-positive breast cancer, development of the so-called Y537S mutation signals that their disease has taken an aggressive course and may become resistant to ...

Please provide your email address to receive an email when new articles are posted on . “Endocrine therapy is the mainstay of treatment for patients with localized and metastatic ...

“This triple therapy approach could be a game-changer for patients whose (breast) cancers no longer respond to standard hormone treatments,” said Rumela Chakrabarti, Ph.D., the study’s senior author ...

Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian dysfunction that drives infertility, menstrual irregularity, and long-term ...

Epigenome remodeling, including widespread changes to DNA methylation and 3D chromatin structure, is increasingly recognized as an important mechanism of gene deregulation in cancer. For example, at ...